Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Receivables (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Receivables for 13 consecutive years, with $2.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Receivables changed N/A to $2.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $2.0 million, a N/A change, with the full-year FY2024 number at $1.2 million, changed N/A from a year prior.
  • Receivables was $2.0 million for Q2 2025 at Plus Therapeutics, up from $1.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $2.0 million in Q2 2025 to a low of $1.2 million in Q4 2024.